Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmith & Nephew Regulatory News (SN.)

Share Price Information for Smith & Nephew (SN.)

Share Price is delayed by 15 minutes
Get Live Data
1,156.50    -4.00 (-0.34%)
Bid:
1,156.00
Ask:
1,157.00
Spread: 1.00 (0.087%)
Market Cap: £9.82b
SN. Live PriceLast checked at - London Stock Exchange

Intraday Smith & Nephew Share Chart

Acquisition

17 Apr 2019 17:21

RNS Number : 5498W
Smith & Nephew Plc
17 April 2019
 

Smith & Nephew Completes Acquisition of Leaf Healthcare, Inc.

17 April 2019

 

Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, announces it has completed the acquisition of Leaf Healthcare, Inc., the developer of the unique Leaf Patient Monitoring System to monitor the orientation and activity of patients susceptible to pressure ulcers. The transaction follows Smith & Nephew's successful two-year partnership with Leaf Healthcare as an exclusive distributor and strategic investor.

The Leaf Patient Monitoring System is a small, lightweight, wearable sensor that wirelessly monitors a patient's position and their mobility whilst in hospital. The tracking data is used to automate and document compliance with prescribed turn protocols for patients at risk of pressure injuries1. Leaf, together with Smith & Nephew's ALLEVYN LIFE and ALLEVYN GENTLE BORDER and SECURA Skin Care products, offers customers a portfolio to help optimise pressure injury prevention protocols.

The commercial terms of the acquisition have not been disclosed. Leaf is currently only available in the US.

 

ENDS

Enquiries

Investors

Andrew Swift +44 (0) 20 7960 2285Smith & Nephew

Media

Charles Reynolds +44 (0) 1923 477314Smith & NephewAbout Smith & Nephew

Smith & Nephew is a portfolio medical technology business with leadership positions in Orthopaedics, Advanced Wound Management and Sports Medicine. Smith & Nephew has more than 16,000 employees and a presence in more than 100 countries. Annual sales in 2018 were $4.9 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN). For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com and follow us on TwitterLinkedIn or Facebook.

References

1. Pickham, D., Pihulic, M., Valdez, A., et al. Pressure injury prevention practices in the ICU: Real-world data captured by wearable patient sensors. Wounds. 2018.

For detailed product information, including indications for use for use, contraindications, precautions and warnings, please consult each products Instructions for Use (IFU) prior to use.

 

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACQEAKLXFFPNEFF
Date   Source Headline
10th Sep 202010:26 amRNSAdditional Listing
1st Sep 20202:00 pmRNSTotal Voting Rights
27th Aug 202011:00 amRNSDirector/PDMR Shareholding
25th Aug 202012:00 pmRNSDirector/PDMR Shareholding
24th Aug 202012:00 pmRNSDirector/PDMR Shareholding
19th Aug 20202:00 pmRNSDirector/PDMR Shareholding
3rd Aug 20202:30 pmRNSBlock listing Interim Review
3rd Aug 202011:59 amRNSTotal Voting Rights
31st Jul 20203:30 pmRNSDirector/PDMR Shareholding
29th Jul 20207:00 amRNSHalf-year Report
13th Jul 202010:45 amRNSDirector/PDMR Shareholding
8th Jul 20208:06 amRNSNotice of Results
1st Jul 202011:09 amRNSTotal Voting Rights
1st Jul 20207:00 amRNSTrading Statement
18th Jun 202012:08 pmRNSSecond Price Monitoring Extn
18th Jun 202012:03 pmRNSPrice Monitoring Extension
1st Jun 202011:53 amRNSTotal Voting Rights
1st Jun 202011:43 amRNSAdditional Listing
27th May 202010:00 amRNSDirector/PDMR Shareholding
22nd May 20202:00 pmRNSDirector/PDMR Shareholding
15th May 20201:30 pmRNSDirector/PDMR Shareholding
13th May 20205:48 pmRNSDirector/PDMR Shareholding
7th May 20205:38 pmRNSDirector/PDMR Shareholding
6th May 20207:00 amRNSTrading Statement
1st May 202012:01 pmRNSTotal Voting Rights
27th Apr 202012:46 pmRNSNSM upload of Articles of Association
23rd Apr 20208:18 amRNSDividend Declaration
15th Apr 202010:00 amRNSNotice of Results
9th Apr 20202:36 pmRNSResult of AGM
9th Apr 202012:02 pmRNSPrice Monitoring Extension
9th Apr 20207:01 amRNSBob White to join Smith+Nephew’s Board as NED
9th Apr 20207:00 amRNSSmith+Nephew appoints Anne-Francoise Nesmes as CFO
6th Apr 20209:00 amRNSAdditional Annual General Meeting update
1st Apr 202012:36 pmRNSTotal Voting Rights
1st Apr 20209:30 amRNSDirector/PDMR Shareholding
30th Mar 20207:01 amRNSAnnual General Meeting update
30th Mar 20207:00 amRNSStatement on COVID-19 impact
26th Mar 20204:41 pmRNSSecond Price Monitoring Extn
26th Mar 20204:36 pmRNSPrice Monitoring Extension
26th Mar 20203:23 pmRNSDirector/PDMR Shareholding
24th Mar 20204:43 pmRNSSecond Price Monitoring Extn
24th Mar 20204:39 pmRNSPrice Monitoring Extension
20th Mar 20204:47 pmRNSSecond Price Monitoring Extn
20th Mar 20204:38 pmRNSPrice Monitoring Extension
18th Mar 20204:38 pmRNSPrice Monitoring Extension
10th Mar 20205:32 pmRNSDirector/PDMR Shareholding
9th Mar 20205:06 pmRNSDirector/PDMR Shareholding
5th Mar 202012:55 pmRNSHolding(s) in Company
5th Mar 20207:01 amRNSDirectorate Change
5th Mar 20207:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.